She, Rui http://orcid.org/0000-0002-3696-6419
Suvitaival, Tommi http://orcid.org/0000-0002-2583-4912
Andersen, Henrik U. http://orcid.org/0000-0001-8048-9720
Hommel, Eva http://orcid.org/0000-0001-7570-5919
Nørgaard, Kirsten http://orcid.org/0000-0003-1620-8271
Wojtaszewski, Jørgen F. P. http://orcid.org/0000-0001-8185-3408
Legido-Quigley, Cristina http://orcid.org/0000-0002-4018-214X
Pedersen-Bjergaard, Ulrik http://orcid.org/0000-0003-0588-4880
Funding for this research was provided by:
Novo Nordisk Fonden (NNF17OC0028358)
Research Foundation at Nordsjællands Hospital
Copenhagen University
Article History
Received: 20 September 2023
Accepted: 3 January 2024
First Online: 1 March 2024
Acknowledgements
: Charlotte Hansen, Pernille Banck-Petersen, Rikke Carstensen and Stine Tving Kjøller from the department of Endocrinology and Nephrology, Nordsjællands Hospital, Hillerød, Denmark, are gratefully acknowledged for their contribution as research nurses. The authors thank Ismo Mattila from Steno Diabetes Center Copenhagen (Herlev, Denmark) and Betina Bolgren and Johan Onslev from the Department of Nutrition, Exercise and Sports, University of Copenhagen (Copenhagen, Denmark) for insightful discussions on the data and their technical assistance. Some of the data were presented as an abstract at the EASD meeting in 2023.
: All data supporting the findings of this study are available within the paper and . Additional datasets are available from the corresponding author upon reasonable request.
: This study was funded by the Novo Nordisk Foundation (grant number NNF17OC0028358) and the Research Foundation at Nordsjællands Hospital. The funding bodies were not involved in the design of the study, collection, analysis or interpretation of data, or writing the report, and did not impose any restrictions regarding publication of the report.
: KN serves as a consultant for Medtronic, Abbott, Convatec and Novo Nordisk, owns stocks in Novo Nordisk, has received research funding from Novo Nordisk, Zealand Pharma, Dexcom and Medtronic, and has received speaking fees from Medtronic, Novo Nordisk and Dexcom. JFPW has current collaborations with Novo Nordisk and Pfizer, unrelated to the present study. HUA owns stocks in Novo Nordisk, has served as an advisor to Novo Nordisk, Abbott and Astra Zeneca, and has received a lecture fee from Nordic Infucare. UP-B is a member of the editorial board of <i>Diabetologia</i>, has served as an advisor to Novo Nordisk, Sanofi and Vertex, and has received lecture fees from Abbott, Novo Nordisk and Sanofi. RS, TS, EH and CL-Q declare that there are no relationships or activities that might bias, or be perceived to bias, their work.
: UP-B and RS contributed to the conceptualisation of the aims of this study. UP-B, RS and JFPW contributed to development of the methodological design. RS, UP-B, KN, HUA and EH contributed to recruitment of participants and execution of the study. RS, TS, UP-B and CL-Q contributed to the data analysis. RS wrote the first draft of the manuscript. UP-B, KN, CL-Q, TS, JFPW, HUA and EH contributed to review and editing of the manuscript. All authors reviewed the results and approved the final version of the manuscript. UP-B is the guarantor of this work, had full access to all the data in the study, and takes responsibility for the integrity and accuracy of the data and data analysis.